Hackstein Holger, Amoros Jose Jaime Verdu, Bein Gregor, Woessmann Wilhelm
Institute for Clinical Immunology and Transfusion Medicine, Justus-Liebig-University Giessen, Giessen, Germany.
Transfusion. 2014 Aug;54(8):2022-7. doi: 10.1111/trf.12596. Epub 2014 Mar 25.
Extracorporeal photopheresis (ECP) is an important cell-based therapy for graft-versus-host disease (GVHD); however, the blood volume required per treatment to achieve a clinical response is unknown.
We developed a mini-ECP technique (mini-ECP) using only 100 to 200 mL of whole blood for patients with contraindications for apheresis or low body weight. Sixteen patients (n=13 acute, n=3 chronic GVHD) with a median body weight of 19 kg (range, 7-48 kg) received 460 mini-ECP treatments with a median duration of 115 days (range, 49-973 days).
Mini-ECP was well tolerated, and acute GVHD resolved completely in nine of 13 patients and partially in two patients but not in two patients. Cutaneous chronic GVHD exhibited a mixed response (one complete, one partial, and one no response).
These results indicate mini-ECP as a novel and less invasive therapy for patients with GVHD and contraindications for apheresis.
体外光化学疗法（ECP）是治疗移植物抗宿主病（GVHD）的一种重要的基于细胞的疗法；然而，每次治疗达到临床反应所需的血量尚不清楚。
我们开发了一种微型ECP技术（mini-ECP），仅使用100至200毫升全血，用于有单采禁忌证或体重低的患者。16例患者（n = 13例急性，n = 3例慢性GVHD），中位体重为19千克（范围7 - 48千克），接受了460次mini-ECP治疗，中位疗程为115天（范围49 - 973天）。
Mini-ECP耐受性良好，13例急性GVHD患者中9例完全缓解，2例部分缓解，2例未缓解。皮肤慢性GVHD表现为混合反应（1例完全缓解，1例部分缓解，1例无反应）。
这些结果表明，mini-ECP是一种适用于有GVHD且有单采禁忌证患者的新型微创疗法。
